Medical Device Procurement in Belgium: A Supplier's Guide [2026]

Belgium may be one of Europe's smaller economies by size, but it is among the most strategically significant for medical device market entry. Home to the European Union's administrative headquarters, NATO, and the European headquarters of numerous global pharmaceutical and medtech organisations, Belgium combines a sophisticated healthcare system, world-class academic medical centres, and a forward-looking digital health agenda. The medical device market is valued at approximately EUR 2.5–3.5 billion annually and is characterised by high per-capita healthcare spending, demanding procurement standards, and strong clinical adoption of innovative technologies.

This guide covers the regulatory pathway, reimbursement framework, procurement system, and practical strategies for winning Belgian hospital tenders in 2026.

Regulatory authority and approval pathway

Belgium operates fully under the EU Medical Device Regulation (MDR 2017/745). The national competent authority is the Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten (FAMHP) — Agence fédérale des médicaments et des produits de santé — the Federal Agency for Medicines and Health Products, responsible for market surveillance, vigilance reporting, and national enforcement of EU MDR.

• CE marking under EU MDR: All medical devices placed on the Belgian market must carry a valid CE mark issued by an EU MDR-designated Notified Body. MDD-era certificates are not accepted for new market placements. Belgian hospital procurement authorities — particularly academic centres — are rigorous in verifying MDR certificate validity, scope coverage, and Notified Body designation status during technical evaluation.
• EUDAMED registration: Devices must be fully registered in the European Database on Medical Devices with UDI (Unique Device Identification) completed at the device, package, and higher packaging levels as required by MDR Annex VI. Belgian hospital procurement teams increasingly cross-reference EUDAMED records during supplier qualification screening.
• Authorised Representative: Non-EU manufacturers must appoint an EU Authorised Representative under Article 11 of EU MDR, with the representative's address on device labelling and in EUDAMED.
• Vigilance reporting to FAMHP: Serious incidents and field safety corrective actions must be reported to FAMHP within the timelines specified in EU MDR Articles 87–90. FAMHP participates in the European vigilance reporting network and collaborates closely with the European Commission's medical device market surveillance coordination.
• National device notification: FAMHP may require additional national notifications for specific device categories beyond EUDAMED registration. Verify applicable requirements for your device class with FAMHP or your EU Authorised Representative before initiating Belgian market placement.

If you already hold EU MDR certification, you have the regulatory foundation for Belgium. The most distinctive aspects of Belgian market entry are the RIZIV/INAMI reimbursement process and the country's complex linguistic and administrative procurement structure.

The RIZIV/INAMI reimbursement system

The RIZIV/INAMI (Rijksinstituut voor ziekte- en invaliditeitsverzekering / Institut national d'assurance maladie-invalidité — National Institute for Health and Disability Insurance) is Belgium's national health insurance body and one of the most consequential actors in medical device market access. Understanding RIZIV/INAMI is essential for any supplier targeting Belgian hospital adoption at scale.

RIZIV/INAMI manages medical device reimbursement through several mechanisms:

• Implant and invasive device reimbursement list: Implants and invasive devices requiring public reimbursement must be listed on the RIZIV/INAMI implant nomenclature. The listing process is managed by the Commission de remboursement des implants et des dispositifs médicaux invasifs (CRIDMI), which evaluates clinical evidence, comparative effectiveness, and cost-effectiveness. Full CRIDMI evaluation typically takes 18–30 months for new device categories.
• Article 35 early access procedure: Innovative devices with significant therapeutic benefit can access interim reimbursement under Article 35 of the Royal Decree while the full CRIDMI evaluation is ongoing. This pathway is strategically important for manufacturers launching novel devices into the Belgian market — it provides a reimbursement-enabled commercial pathway without waiting for the full listing process to complete.
• APR-DRG hospital financing: Belgian hospitals are financed through an All Payer DRG (APR-DRG) system administered by RIZIV/INAMI. Medical devices used during hospitalised procedures are in many cases absorbed within the DRG tariff — meaning hospitals bear device costs against DRG revenue. Understanding how your device affects the hospital's APR-DRG financial position is important for procurement committee decision-making, particularly for implants and capital equipment.
• NIHDI "lump-sum" conventions: For some outpatient and chronic care device categories, RIZIV/INAMI uses convention-based reimbursement (forfait) that operates differently from the standard nomenclature listing. Devices targeting home care, ambulatory monitoring, or chronic condition management may qualify under specific RIZIV/INAMI convention frameworks.

RIZIV/INAMI listing is not always a prerequisite for hospital procurement — hospitals can purchase non-listed devices within their operational budgets. However, for implants and higher-cost devices where patient-level reimbursement matters, RIZIV/INAMI listing substantially accelerates adoption by hospital purchasing committees and clinical departments. Starting the reimbursement application concurrently with CE marking certification — not sequentially — is the most time-efficient market access strategy.

Key procurement platforms and channels

Belgian public hospital procurement follows the Wet Overheidsopdrachten / Loi sur les marchés publics (Public Procurement Act), which implements EU procurement directives. Belgium's procurement infrastructure is highly digitalised and centralised through federal platforms:

• eProcurement.be: Belgium's federal electronic procurement platform, covering e-Notification (contract publication), e-Tendering (electronic submission), e-Catalogue, and e-Auction functions. All public hospital tenders above thresholds are published and managed through this platform. Belgium's eProcurement infrastructure is among the most advanced in Europe, with mandatory electronic publication and submission for all contracts above the EU publication threshold.
• TED (Tenders Electronic Daily): All Belgian public contracts above EU supply thresholds (EUR 215,000) are simultaneously published on TED. Major hospital group framework agreements and capital equipment tenders appear on both eProcurement.be and TED.
• Individual hospital and hospital group portals: Academic and specialist hospitals often publish procurement notices on their own platforms in addition to the federal system. Key academic centres include UZ Leuven (Flemish Belgium's largest), UZ Gent, UZ Brussel (VUB), CHU de Liège, Cliniques Universitaires Saint-Luc (UCLouvain in Brussels), and Erasme Hospital (ULB Brussels). These institutions are high-volume buyers and important clinical reference sites for the European market.
• NONA and hospital purchasing groups: Several hospital purchasing networks coordinate group procurement to achieve better pricing, standardisation, and administrative efficiency. The NONA network is a significant hospital purchasing alliance in Flanders. Winning a group purchasing agreement provides access to multiple hospitals through a single commercial process without individual hospital-by-hospital tender participation.

Monitoring eProcurement.be, TED, and individual academic hospital portals across Belgium's Dutch-speaking, French-speaking, and bilingual Brussels procurement environments requires structured attention. MedStrato's tender monitoring consolidates Belgian procurement opportunities into a single feed across all official channels.

Belgium's linguistic and administrative procurement structure

Belgium's federal structure — with three language communities (Dutch-speaking Flanders, French-speaking Wallonia, and bilingual Brussels-Capital Region) and overlapping administrative competencies between federal and regional levels — creates procurement requirements that vary significantly by contracting authority:

• Flanders: Hospital tenders published in Dutch. Flemish hospital purchasing is increasingly coordinated through Zorgnet-Icuro (the Catholic hospital network) and joint purchasing initiatives among Flemish hospital groups. UZ Leuven and UZ Gent set clinical procurement standards that influence adoption decisions throughout the Flemish hospital system.
• Wallonia: Hospital tenders published in French. The Walloon region's hospital network includes major CHU (Centre Hospitalier Universitaire) institutions in Liège, Charleroi, and Namur, as well as the Cliniques Saint-Luc network. French-language commercial and clinical capabilities are essential for effective Walloon market engagement.
• Brussels-Capital Region: Belgium's bilingual capital hosts 19 municipalities and hospital systems serving both French- and Dutch-speaking communities. Tender documents may be published in French, Dutch, or both, depending on the contracting authority. Erasme Hospital, CHU Saint-Pierre, and UZ Brussel are the main academic buyers in Brussels.

For practical purposes, foreign suppliers targeting the full Belgian market need both French-language and Dutch-language capabilities for tender documentation. Submitting only in English may be acceptable for purely technical datasheets in some contexts, but procurement submission documents must match the official language of the contracting authority.

Compliance requirements for Belgian hospital tenders

• Language: Tender submissions must be in the official language(s) of the contracting authority — French in Wallonia, Dutch in Flanders, French and/or Dutch in Brussels. Technical documentation, IFU, and product labelling must be translated accordingly.
• EU MDR compliance documentation: Valid CE certificate under EU MDR, current EUDAMED registration, UDI assignment, and — for implantable and Class III devices — SSCP (Summary of Safety and Clinical Performance) documentation. Belgian procurement authorities, particularly academic hospitals, are thorough in verifying MDR documentation. See EU MDR tender requirements 2026 for the full compliance checklist.
• ISO 13485 certification: Quality management system certification is standard for all medical device procurement. Belgian hospital procurement authorities may additionally request EN ISO 14971 risk management documentation and, for software-enabled devices, IEC 62304 compliance evidence.
• Environmental and sustainability criteria: Belgium is among the EU's more advanced markets in integrating Green Public Procurement criteria. Tenders for hospital consumables, single-use devices, and capital equipment increasingly include environmental scoring criteria covering packaging, recyclability, energy efficiency, and carbon footprint. Prepare sustainability documentation proactively for Belgian tenders.
• Social responsibility clauses: Belgian public procurement frequently includes social responsibility requirements under the Wet Overheidsopdrachten framework, covering supply chain ethics, labour standards, and diversity. These clauses have become significantly more prevalent since 2024 and are now routine in major hospital framework tenders.

Market size and opportunity

Belgium's medical device market is valued at approximately EUR 2.5–3.5 billion annually. Despite a population of only 11.5 million, Belgium's per-capita healthcare spending ranks among the highest in the EU — supporting strong medical device procurement volumes relative to population size. Key opportunity segments include:

• Implants and interventional devices: Belgium's academic medical centres are high adopters of advanced implantables — cardiovascular, orthopaedic, neuro-modulation, and spinal systems. RIZIV/INAMI listing for implants creates durable, reimbursed procurement volumes across the hospital network.
• Robotic surgery and advanced OR technology: Belgian academic hospitals are consistent early adopters of surgical innovation. UZ Leuven and CHU Liège are well-established reference centres for robotic surgery platforms, with procurement volumes for advanced surgical systems consistently strong.
• Diagnostics and laboratory systems: Belgium has a dense network of hospital and independent laboratories. Framework contracts for diagnostic reagents, clinical chemistry analysers, and point-of-care testing systems represent significant procurement value across Flanders, Wallonia, and Brussels.
• Digital health and Software as a Medical Device (SaMD): Belgium has active digital health reimbursement pathways (mHealthBelgium and the m.a.d. trajectory for validated health applications), creating procurement pathways for SaMD products with RIZIV/INAMI reimbursement support. Belgian academic hospitals are significant pilot partners for digital health innovation across Europe.

Tips for foreign suppliers entering Belgium

1. Initiate RIZIV/INAMI reimbursement early: For implants and invasive devices, the CRIDMI evaluation process takes 18–30 months for new categories. Starting the reimbursement application concurrently with CE marking — not after CE certificate issuance — substantially shortens time to reimbursed market access. The Article 35 early access pathway provides a commercial bridge during the evaluation period.
2. Address the language duality proactively: Prepare commercial and clinical materials in both French and Dutch. While this increases upfront investment, the Belgian market effectively contains two linguistically separate procurement communities. Targeting only one language leaves significant procurement volume unaddressed and signals limited commitment to the full market.
3. Establish academic medical centre reference sites: Belgian academic hospitals carry substantial influence as European clinical reference centres. A clinical adoption at UZ Leuven or Cliniques Saint-Luc accelerates procurement decisions across the Flemish and Walloon hospital systems respectively, and provides a credible European reference for broader EU market entry discussions.
4. Engage hospital purchasing groups early: Approaching the NONA network and equivalent Walloon hospital purchasing alliances early in your commercial strategy provides access to multiple hospitals through a single negotiation. GPO-equivalent pricing agreements with hospital purchasing groups are the most efficient commercial pathway for standard device categories in Belgium.
5. Track EU-funded digital health opportunities: Belgium is an active beneficiary of EU Horizon Europe and Digital Europe Programme funding for healthcare digitisation, generating procurement opportunities for digital health devices and SaMD with different evaluation criteria and timelines compared to routine hospital consumable tenders. Book a MedStrato demo to see how EU-funded Belgian procurement opportunities are tracked alongside routine hospital tenders across all official portals.

Common rejection reasons in Belgian tenders

The most frequent technical rejection reasons for medical device suppliers in Belgian hospital procurement include:

• Submitting in the wrong language (English where French or Dutch is required by the contracting authority)
• MDD-era CE documentation or EU MDR certificates that expired before or during the submission period
• Missing RIZIV/INAMI listing for implant categories where reimbursement status is a scored qualification criterion
• Incomplete EUDAMED registration or UDI data inconsistencies between the EUDAMED record and the certificate submitted
• ISO 13485 certificate from an unaccredited certification body or near expiry at submission
• Insufficient clinical evidence for Class IIb and Class III device categories subject to CRIDMI evaluation requirements
• Missing environmental and sustainability documentation for tenders with Green Public Procurement scoring criteria

Automated compliance verification before submission prevents most EU MDR documentation failures. MedStrato verifies CE certificate validity, EUDAMED registration status, and UDI compliance against each tender's specific requirements before submission, flagging gaps in real time so your team can resolve them before the deadline.

Ready to pursue Belgium's hospital tender market? Book a demo to see how MedStrato handles Belgian tender compliance and multi-language monitoring, or explore the full feature set for multi-market medical device tender management.